Market News AIOpen the app

JPMorgan lowered its price target for BridgeBio Oncology Therapeutics from $23 to $17.

OpinionRead the original at moomoo.com
Bad for BBOT

JPMorgan lowered its share target, signaling a less favorable view of BBOT shares. The report gives no new company results, so this is a negative analyst opinion rather than news of a business setback.

BBOT · BridgeBio Oncology Therapeutics, Inc.

AI read · Bad for BBOT

The AI's read

That change shows JPMorgan now sees less value in BBOT's shares. The report gives no new trial results or other business updates, so the negative signal comes from the firm's changed opinion rather than a reported setback at the company.

Get alerts for BBOT

Follow BridgeBio Oncology Therapeutics, Inc. (BBOT) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for BBOT
Free on the App Store and Google Play, or on the web.